Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Intranasal dhe for the treatment of headache

Inactive Publication Date: 2016-08-11
SATSUMA PHARMA INC
View PDF20 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a powder formulation of dihydroergotamine (DHE) for the treatment of headaches, particularly migraines, using a nasal spray. The formulation includes DHE and a carrier called microcrystalline cellulose. The powder formulation can be administered to humans and has been found to have a rapid onset of action and a long duration of effect. The technical effects of this patent include providing a more effective and convenient method for treating headaches with a powder formulation of DHE.

Problems solved by technology

Migraine is a very common, often debilitating, form of headache.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intranasal dhe for the treatment of headache
  • Intranasal dhe for the treatment of headache
  • Intranasal dhe for the treatment of headache

Examples

Experimental program
Comparison scheme
Effect test

example 1

6.1 Example 1

Preparation of DHE Powder Formulations

[0132]6.1.1 Preparation of 0.1 Mg DHE Powder Formulation

[0133]Powder formulations comprising 0.1 mg DHE were prepared as described herein.

[0134]Materials.

[0135]Dihydroergotamine mesylate (99.7% purity; primary particle distribution: Dv10: 5.3 μm; Dv50: 17.7 μm; Dv90: 69.3 μm; “DvX” refers to the maximum particle diameter below which X % of the sample exists; for example, “Dv10” refers to the maximum particle diameter below which 10% of the sample exists); microcrystalline cellulose, Ceolus® PH-F20JP (nominal particle size: 20 μm, less than 1% retained when sieved through mesh size 400; Asahi Kasei Chemicals Corporation); Microcrystalline cellulose, Ceolus® PH-301 (nominal particle size: 50 μm, less than 1% retained when sieved through mesh size 60 and less than 30% retained when sieved through mesh size 200; Asahi Kasei Chemicals Corporation); Tribasic calcium phosphate (Ca5(OH)(PO4)3; Mallinckrodt Chemicals); HPMC capsule, size 2, ...

example 2

6.2 Example 2

Pharmacokinetic Study of Intranasal Dihydroergotamine Formulations in Primates

[0154]The study described herein is designed to assess the pharmacokinetics of plasma dihydroergotamine (DHE) and 8′-hydroxy DHE levels after intranasal administration using DHE powder formulations described herein, and to compare the pharmacokinetic profiles achieved via intranasal administration of such formulations with those of comparative DHE formulations administered via various dosing routes.

[0155]The study utilizes Cynomolgus monkeys (macaca fascicularis, purpose bred) because the nasal cavity of such monkeys is morphologically similar to that in humans, and is commonly used as an experimental animal.

[0156]Methods.

[0157]Animals.

[0158]Six male Cynomolgus monkeys (macaca fascicularis, purpose bred), 4 to 6 years old are used, following accredited animal welfare standards.

[0159]Test Powder Formulations.

[0160]Powder formulations containing 0.1 mg DHE, 0.5 mg DHE and 1.0 mg DHE, as describe...

example 3

6.3 Example 3

A Randomized, Open-Label, 5-Way Crossover Study to Evaluate the Pharmacokinetics, Dose Proportionality, Safety, and Tolerability of Single Doses of Dihydroergotamine 1, 1.5, 2 and 3 mg Intranasal Powder and Assess the Relative Bioavailability to Dihydroergotamine 1 mg Administered Subcutaneously as a Solution in Healthy Volunteers

[0178]The study described herein is designed to determine the pharmacokinetic profile, dose-proportionality, safety and tolerability of DHE intranasal powder 1 mg, 1.5 mg, 2 mg and 3 mg in young healthy subjects and compare its bioavailability with DHE 1 mg administered subcutaneously as a solution. The pharmacokinetics of DHE and its metabolite (8′-β-hydroxydihydroergotamine; 8′-β-OH-DHE) are characterized in this study.

[0179]Methodology.

[0180]This is a single-center, single-dose, randomized, open-label, 5-way crossover, pharmacokinetic and safety study. Thirty (30) eligible subjects, not less than 40% or more than 60% of either gender, receiv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

Description

1. CROSS-REFERENCE[0001]This application claims priority to U.S. Provisional Patent Application Ser. No. 61 / 881,947, filed Sep. 24, 2013, which is entirely incorporated herein by reference.2. BACKGROUND[0002]Migraine is a very common, often debilitating, form of headache. Typically the headache is unilateral (affecting one half of the head) and pulsating in nature. In addition to head pain, associated symptoms may include nausea, vomiting, photophobia, (increased sensitivity to light), and phonophobia (increased sensitivity to sound). Migraines can also be associated with “auras,” which are transient visual, sensory, language, or motor disturbances often manifest as flashes of colored or blinking lights that occur shortly before the onset of head pain.[0003]Symptomatic treatment of migraine generally involves administration of triptans, such as sumatriptan or zolmitriptan, or ergot alkaloids, such as ergotamine or dihydroergotamine. While various routes of administration of these dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4985A61K47/22A61K9/14A61K47/02A61K47/38A61K9/00
CPCA61K9/0043A61K9/146A61K31/48A61K45/06A61K31/4985A61K31/522A61K47/38A61K47/22A61K47/02A61K2300/00A61P25/06A61P43/00
Inventor HARUTA, SHUNJISINGH, NIKHILESH N.KOLLINS, JOHNRICO, SALVADOR
Owner SATSUMA PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com